Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15529598 | 0.92 | ALDH1A1 (0.41) | ALDH1A1TSHRCA1CA2LOX | |
| Ether SCHEMBL6610151 | 0.87 | CA2 (0.33) | CA1CA2 | |
| SCHEMBL1161080 | 0.84 | ALDH1A1 (0.39) | ALDH1A1TSHRKDM4ELMNAHTT | |
| SCHEMBL28937510 | 0.82 | CA2 (0.50) | CA1CA2 | |
| SCHEMBL12056659 | 0.81 | ALDH1A1 (0.50) | ALDH1A1TSHRTHRB | |
| SCHEMBL18177089 | 0.79 | CA2 (0.38) | ALDH1A1TSHRLMNAHTTCA1 | |
| SCHEMBL4359971 | 0.79 | CA2 (0.40) | TSHRCA1CA2 | |
| SCHEMBL277716 | 0.78 | ALDH1A1 (0.31) | ALDH1A1TSHR | |
| SCHEMBL152599 | 0.78 | — | — | |
| SCHEMBL13173432 | 0.77 | CA2 (0.33) | TSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140044672-A1 | CONJUGATES OF A GM-CSF MOIETY AND A POLYMER | NEKTAR THERAPEUTICS (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130096258-A1 | POLYMER CONJUGATES OF GLP-1 | NEKTAR THERAPEUTICS (US) | 2013-04-18 | — | — | US | disclosed |
| US-8293869-B2 | Polymer conjugates of GLP-1 | NEKTAR THERAPEUTICS (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110171161-A1 | POLYMER CONJUGATES OF PROTEGRIN PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171163-A1 | POLYMER CONJUGATES OF ZICONOTIDE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110165113-A1 | POLYMER CONJUGATES OF V681-LIKE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100210505-A1 | POLYMER CONJUGATES OF GLP-1 | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171163-A1 | POLYMER CONJUGATES OF ZICONOTIDE PEPTIDES | NGLY1, VIP, IAPP | ALDH1A1 4383/4885TSHR 1342/4885KDM4E 4774/4885 |
| US-20100210505-A1 | POLYMER CONJUGATES OF GLP-1 | GLP1R, GIPR, NGLY1 | ALDH1A1 3046/4885TSHR 1453/4885KDM4E 1193/4885 |
| US-20130096258-A1 | POLYMER CONJUGATES OF GLP-1 | GLP1R, GIPR, NGLY1 | ALDH1A1 2730/4885TSHR 1056/4885KDM4E 1378/4885 |
| US-20110171161-A1 | POLYMER CONJUGATES OF PROTEGRIN PEPTIDES | PSMG3, PSMB11, PSMC5 | ALDH1A1 4840/4885TSHR 3722/4885KDM4E 4396/4885 |
| US-20140044672-A1 | CONJUGATES OF A GM-CSF MOIETY AND A POLYMER | CSF3R, GMFG, CSF1R | ALDH1A1 2146/4885TSHR 3521/4885KDM4E 4113/4885 |
| US-20110165113-A1 | POLYMER CONJUGATES OF V681-LIKE PEPTIDES | NGLY1, VIP, DNPEP | ALDH1A1 3859/4885TSHR 2797/4885KDM4E 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.